At what enterprise value was SYNLAB SPAIN acquired in 2025?

You can find the full valuation details of SYNLAB SPAIN on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of SYNLAB SPAIN when it was acquired by EUROFINS SCIENTIFIC?

The exact EV/EBITDA multiple for SYNLAB SPAIN is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was SYNLAB SPAIN acquired by EUROFINS SCIENTIFIC?

SYNLAB SPAIN was acquired by EUROFINS SCIENTIFIC in 2025.

What was the revenue of SYNLAB SPAIN at the time of the deal?

The revenue of SYNLAB SPAIN at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the SYNLAB SPAIN acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SYNLAB SPAIN deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.synlab.com/news-updates/read-article/synlab-agrees-to-sell-its-spanish-business-to-eurofins-1532953

← DATABASE

Home Database Healthcare & PharmaSYNLAB SPAIN

04/2025

SYNLAB SPAIN acquired by EUROFINS SCIENTIFIC

SPAIN Health Providers / Healthcare Facilities / Labs (Biology) REV 100M - 200M EUR

Context

Eurofins Scientific has completed the acquisition of 100% of SYNLAB’s clinical diagnostics operations in Spain. The transaction, initially agreed upon in October 2024, was finalized on March 31, 2025. This strategic carve-out allows SYNLAB to optimize its portfolio by exiting the Spanish market to focus on regions with higher strategic impact. For Eurofins, the acquisition is transformative, merging SYNLAB’s assets with its existing Eurofins Megalab network to become the undisputed leader in clinical diagnostics in Spain. The combined entity now possesses a workforce of over 2,000 employees and the capacity to serve more than 10 million patients annually, processing over 100 million tests. The strategic rationale centers on total geographic coverage of Spain and enhanced capabilities in specialized testing such as genetics. The deal was integrated without significant restructuring due to the complementary nature of the laboratory footprints.

By taking control of Synlab Spain, Eurofins Scientific continues its expansion strategy. Previously, the group had completed 2 acquisitions, including Covance Food Solutions in 2018.

SYNLAB SPAIN, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

SYNLAB Spain is a leading provider of medical diagnostic services and specialty testing in the Spanish market. The organization provides a comprehensive range of clinical diagnostic tests, with specialized expertise in clinical genetics and anatomical pathology. Operating through an extensive network of laboratories and blood collection points, the entity serves both public and private clients across all regions of Spain. The business model focuses on high-quality, technologically advanced testing services, processing millions of laboratory tests annually. Prior to its acquisition, the unit was a core component of the German-headquartered SYNLAB Group, maintaining a highly specialized workforce and a strong reputation for scientific medical advances in the Iberian Peninsula.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
07/2025	BRIDGEPOINT	MYDENTIST	UNITED KINGDOM	Health Providers	Bridgepoint acquired MyDentist from its long-term owners (likely Palamon Capital Partners and The Carlyle Group). Bridgepoint aims to accelerate the group's pivot from low-margin NHS contracts toward high-growth private treatments (implants, aesthetics, clear aligners)
05/2025	FONDATION SANTE SERVICE	CLARIANE HAD (HOME HOSPITALIZATION SERVICES)	FRANCE	Health Providers	Clariane sells its French home hospitalization business to the leader of the sector in France, Fondation Sante Service. The deal is part of Clariane's EUR1bn asset disposal plan to strengthen its balance sheet
12/2024	SONIC HEALTHCARE	LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES	GERMANY	Health Providers	Sonic Healthcare has signed binding agreements to acquire the LADR Laboratory Group, marking a substantial expansion of its German and European diagnostic footprint. The transaction was structured on a cash and debt-free basis, with a total consideration satisfied through a mix of Sonic ordinary shares (up to 222 million euros) and cash funded from existing facilities
12/2024	CAPZA	IMDEV	FRANCE	Health Providers	The transaction involves a primary Owner Buy-Out (OBO) where Capza and Bpifrance acquire a minority stake in Imdev to support its next phase of pan-European scaling. This capital injection includes a significant capital increase and a cash-out component for historical shareholders
11/2024	WELLTOWER	CARE UK	UNITED KINGDOM	Health Providers	Bridgepoint divested its entire stake in Care UK to Welltower, a US healthcare REIT, marking the conclusion of approximately 14 years of private equity ownership. Bridgepoint had originally acquired Care UK in 2010 and had previously attempted an unsuccessful sale process, incurring £2
11/2024	GROUPE IMAGERIE CARDINET	RADIOLOGIE PARIS OUEST	FRANCE	Health Providers	Groupe Imagerie Cardinet acquired 100% of Radiologie Paris Ouest from its previous majority shareholder, Azulis Capital, which had held a stake since 2019. The transaction was financed with the support of Andera Acto (Andera Partners' sponsorless/mezzanine arm), which had already invested in Cardinet in 2023
10/2024	ARDIAN	VISTA VISION	ITALY	Health Providers	Ardian Expansion acquired a majority stake in Vista Vision from its founders and Credem Private Equity. The transaction marks a new strategic phase for the group, following a period of rapid expansion where revenues tripled under Credem's tenure
10/2024	QUALIUM	IMPC (IMAGERIE MEDICALE PARIS CENTRE)	FRANCE	Health Providers	Qualium Investissement is acquiring a 25% minority stake in IMPC from its associate radiologists. This primary LBO transaction follows a strategic period of reflection during which the founding doctors chose to maintain operational and capital control of their group rather than pursuing a majority sale
10/2024	MONTEFIORE INVESTMENT	DEMENEGO	ITALY	Health Providers	Montefiore Investment acquired a majority stake in Demenego from Vam Investments. This secondary LBO follows a highly successful four-year period of ownership by the seller, during which the company more than doubled its revenue and expanded its retail network from 15 to 39 stores
08/2024	ORLANDO HEALTH	BROOKWOOD BAPTIST HEALTH SERVICES	UNITED STATES	Health Providers	Orlando Health signed a definitive agreement to acquire Tenet Healthcare's majority interest in Baptist Health, the faith-based integrated health system operating across Central Alabama. Upon closing, Orlando Health will become the majority and managing partner of Baptist Health, assuming day-to-day operational management of the system in partnership with Baptist Health System, which retains its minority stake and continues to anchor the organisation's faith-based mission

REFERENCES

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SYNLAB SPAIN by EUROFINS SCIENTIFIC are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: eurofins scientific